

Medicine at a Crossroads:


Informatics Driving Discovery and Improving Human Health

Alexa T. McCray, PhD

alexa_mccray@hms.harvard.edu

*Society of Neurological Surgeons
June 9, 2013*


The Promise of Genomic Medicine




1990-2003
Human Genome
Project




2004-2010



2011-2020




Beyond 2020



Green ED. *Nature* 2011; 470(10):203-13

The Promise of Genomic Medicine




Understanding
the structure
of genomes


1990-2003
Human Genome
Project




2004-2010



2011-2020




Beyond 2020



Green ED. *Nature* 2011; 470(10):203-13


The Promise of Genomic Medicine




1990-2003
Human Genome
Project




2004-2010



2011-2020




Beyond 2020



Green ED. *Nature* 2011; 470(10):203-13


The Promise of Genomic Medicine




1990-2003
Human Genome
Project




2004-2010



2011-2020




Beyond 2020



Green ED. *Nature* 2011; 470(10):203-13


The Promise of Genomic Medicine




1990-2003
Human Genome
Project




2004-2010



2011-2020



Beyond 2020



Green ED. *Nature* 2011; 470(10):203-13

The Promise of Genomic Medicine

➤ No longer is data generation the major bottleneck, rather

➤ Computational challenges around

➤ Data analysis

➤ Data display

➤ Data integration

Green ED. Nature 2011; 470(10):203-13.


An Inflection Point

“Biomedical research and the practice of medicine, separately and together are reaching an inflection point: the capacity for description and for collecting data, is expanding dramatically, but the efficiency of compiling, organizing manipulating these data – and extracting true understanding of fundamental biological processes, and insights into human health and disease, from them – has not kept pace.”

Toward Precision Medicine: Building a knowledge network of biomedical research and a new taxonomy of disease. National Research Council, 2011


Precision Medicine

Individual-Centric




Toward Precision Medicine
National Research Council, 2011

Precision Medicine



Toward Precision Medicine
National Research Council, 2011


Precision Medicine



Toward Precision Medicine
National Research Council, 2011

Precision Medicine


Individual-Centric



Toward Precision Medicine
National Research Council, 2011

Precision Medicine


Individual-Centric



Toward Precision Medicine
National Research Council, 2011

A New Taxonomy of Disease

“Could it be that something as fundamental as our current system for classifying diseases is actually inhibiting progress?”



Toward Precision Medicine.
National Research Council, 2011:10

Heterogeneous Data Types

Realizing the Vision

Basic Science Discovery

Clinical Discovery

Laboratory

Laboratory

Text





Text

Images

Images


Signals

Signals




(BIG) Data Sources

GWAS Data



- Variation in level of
- Structure
- Curation (metadata)

Clinical Systems



Biosensor Data



Public Databases

NCBI **Databases and Tools**
National Center for Biotechnology Information

About NCBI	NCBI at a Glance	A Science Primer	Databases and Tools
Human Genome Resources	Model Organisms Guide	Outreach and Education	News

[About NCBI Site Map](#)
[NCBI News](#)
[Subscribe to NCBI-Announce](#)

- Literature Databases
- Entrez Databases
- Nucleotide Databases
- Genome-Specific Resources
- Tools for Data Mining
- Tools for Sequence Analysis
- Tools for 3-D Structure Display and Similarity Searching
- Maps
- Collaborative Cancer Research
- FTP Download Sites
- Resource Statistics

Social Networking Sites





The Cancer Forums
A website for discussions about any type of cancer, including lung cancer, breast cancer, prostate cancer, and more.

patientslikeme®
Username or Email: _____
Remember me


"Because of PatientsLikeMe, we are better able to recognize warning signs... (and) keep things in perspective. In short, PatientsLikeMe empowers us."

"PatientsLikeMe has provided me with new friends - people who are experiencing the same problems as I am."

Terminologies for Curating Biomedical Datasets



➤ Integrates > 100 existing biomedical terminologies



1997: Congress Passes Law (FDAMA) Requiring Trial Registration

The first U.S. Federal law to require trial registration was the [Food and Drug Administration Modernization Act of 1997 \(FDAMA\)](#) (PDF).

Section 113 of FDAMA required that the National Institutes of Health (NIH) create a public information resource on certain clinical trials regulated by the Food and Drug Administration (FDA). Specifically, FDAMA 113 required that the registry include information about federally or privately funded clinical trials conducted under investigational new drug applications (INDs) to test the effectiveness of experimental drugs for patients with serious or life-threatening diseases or conditions.

The information in the registry was intended for a wide audience, including individuals with serious or life-threatening diseases or conditions, members of the public, health care providers, and researchers.

1997 FDMA

2004 ICMJE



Uniform Requirements for Manuscripts Submitted to Biomedical Journals:
[Publishing and Editorial Issues Related to Publication in Biomedical Journals:](#)
[Obligation to Register Clinical Trials](#)

http://www.icmje.org/publishing_10register.html

2007: Congress Passes Law (FDAAA) Expanding ClinicalTrials.gov Submission Requirements

In 2007 the requirements for submission to ClinicalTrials.gov were expanded after Congress passed the [Food and Drug Administration Amendments Act of 2007 \(FDAAA\)](#) (PDF) Section 801 of FDAAA (FDAAA 801) requires more types of trials to be registered; additional trial registration information; and the submission of summary results, including adverse events, for certain trials. The law also included penalties for noncompliance, such as the withholding of NIH grant funding and civil monetary penalties of up to \$10,000 a day.

- ClinicalTrials.gov: See the [FDAAA 801 Requirements](#) page
- NIH Office of Extramural Research: [Frequently Asked Questions: FDAAA - Further Resources for NIH Grantees](#)

2007 FDAAA

ClinicalTrials.gov currently lists **146,692 studies** with locations in all 50 states and in **184 countries**.

Text Size ▼

Search for Studies

Example: "Heart attack" AND "Los Angeles"

[Advanced Search](#) | [See Studies by Topic](#)
[See Studies on a Map](#)

Search Help

- [How to search](#)
- [How to find results of studies](#)
- [How to read a study record](#)

For Patients & Families

- [How to find studies](#)
- [See studies by topic](#)
- [Learn about clinical studies](#)
- [Learn more...](#)

For Researchers

- [How to submit studies](#)
- [Download content for analysis](#)
- [About the results database](#)
- [Learn more...](#)

For Study Record Managers

- [Why register?](#)
- [How to register study records](#)
- [FDAAA 801 Requirements](#)
- [Learn more...](#)

Locations of Recruiting Studies



Total N = 30,211 studies
 Data as of June 07, 2013

- [See more trends, charts, and maps](#)

Learn More

- [ClinicalTrials.gov Online Training](#)
- [Glossary of common site terms](#)

[For the Press](#)

[Using our RSS Feeds](#)

International Scope

Types of Studies

- **Interventional Trials**
 - Drug or Biologic
 - Behavioral
 - Surgical Procedures
 - Devices
- **Observational Studies**
- **Device Trials**

[Find Studies](#) ▾ [About Clinical Studies](#) ▾ [Submit Studies](#) ▾ [Resources](#) ▾ [About This Site](#) ▾

ClinicalTrials.gov currently lists **146,692 studies** with locations in all 50 states and in **184 countries**.

[Text Size](#) ▾

Search for Studies

Example: "Heart attack" AND "Los Angeles"

[Advanced Search](#) | [See Studies by Topic](#)

[See Studies on a Map](#)

Search Help

- [How to search](#)
- [How to find results of studies](#)
- [How to read a study record](#)

Locations of Recruiting Studies



Non-U.S. Only (50%)

U.S. Only (44%)

Both U.S. & Non-U.S. (6%)

Total N = 30,211 studies

Data as of June 07, 2013

- [See more trends, charts, and maps](#)

Learn More

- [ClinicalTrials.gov Online Training](#)
- [Glossary of common site terms](#)

 [For the Press](#)

 [Using our RSS Feeds](#)

For Patients & Families

- [How to find studies](#)
- [See studies by topic](#)
- [Learn about clinical studies](#)
- [Learn more...](#)

For Researchers

- [How to submit studies](#)
- [Download content for analysis](#)
- [About the results database](#)
- [Learn more...](#)

For Study Record Managers

- [Why register?](#)
- [How to register study records](#)
- [FDAAA 801 Requirements](#)
- [Learn more...](#)

[HOME](#)

[RSS FEEDS](#)

[SITE MAP](#)

[TERMS AND CONDITIONS](#)

[DISCLAIMER](#)

[CONTACT NLM HELP DESK](#)

ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Search for studies: Example: "Heart attack" AND "Los Angeles"

[Advanced Search](#) | [Help](#) | [Studies by Topic](#) | [Glossary](#)

[Find Studies](#) | [About Clinical Studies](#) | [Submit Studies](#) | [Resources](#) | [About This Site](#)

Home > Find Studies > Search Results Text Size ▾

467 studies found for: neurosurgery
[Modify this search](#) | [How to Use Search Results](#)

[List](#) | [By Topic](#) | [On a Map](#) | [Search Details](#)

+ Show Display Options

☐ Include only open studies ☐ Exclude studies with unknown status

Rank	Status	Study
1	Recruiting	A Patient Registry at the Neurosurgery Department Condition: Patients Treated at the Neurosurgery Department Intervention: Procedure: Treatment at the neurosurgery departement
2	Recruiting	Risk Factors of Complications Regarding Patients Undergoing Brain Tumour Neuro-surgery (Cranioscore). Conditions: Neuro-surgery,; Brain Tumor,; Post-operative Complications,; Neuro-ICU Stay Intervention: Other: Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications
3	Recruiting	Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery Conditions: Motor Evoked Potential Monitoring; General Anesthesia; Neurosurgery; Brain Tumor; Spine Tumor; Cerebral Aneurysm Interventions: Other: MEP monitoring with continuous infusion of vecuronium during general anesthesia; Other: MEP monitoring with continuous infusion of cisatracurium during general anesthesia
4	Recruiting	Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients Conditions: Tethered Spinal Cord; Brain Tumor; Cranio Cervical Compression Intervention: Other: Isoflurane, Propofol, Dexmedetomidine
5	Completed	Strategy for Maintaining Partial Neuromuscular Blocking Adequate for Motor Evoked Potential During Neurosurgery Conditions: Brain Surgery With Motor Evoked Potential Monitoring; Spine Surgery With Motor Evoked Potential Monitoring Interventions: Other: TOF count guided adjustment; Other: T1/ T0 guided adjustment; Other: T2/ T0 guided adjustment

Several hundred
Neurosurgery
Studies

17 studies found for: neurosurgery AND deep brain stimulation | Open Studies

[Modify this search](#) | [How to Use Search Results](#)

[List](#) [By Topic](#) [On a Map](#) [Search Details](#)

+ [Show Display Options](#)

Download [Subscribe to RSS](#)

☒ Include only open studies ☐ Exclude studies with unknown status

Rank	Status	Study
1	Recruiting	Neurotransmitter Measurements Using Wireless Instantaneous Neurotransmitter Concentration System (WINCS) During Deep Brain Stimulation Neurosurgery Conditions: Essential Tremor; Parkinson's Disease; Dystonia Intervention: Device: WINCS (Wireless Instantaneous Neurochemical Concentration Sensing System)
2	Recruiting	Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Condition: Anorexia Interventions: Procedure: Deep Brain Stimulation(DBS); Procedure: Capsulotomy
3	Recruiting	Sub-thalamic Nucleus Stimulation in Parkinson Disease Condition: Parkinson's Disease Interventions: Procedure: New targeting procedure without electrophysiology; Procedure: Classical neurosurgical procedure
4	Recruiting	SubGenual CG25 Deep Brain Stimulation in Severe Resistant Depression Condition: Depression Intervention:
5	Recruiting	Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder Condition: Obsessive-Compulsive Disorder Intervention: Device: Deep brain stimulation (DBS)
6	Recruiting	Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa Condition: Anorexia Nervosa Intervention: Procedure: Deep Brain Stimulation

17 recruiting studies involving deep brain stimulation

Neurotransmitter Measurements Using Wireless Instantaneous Neurotransmitter Concentration System (WINCS) During Deep Brain Stimulation Neurosurgery

This study is currently recruiting participants.

Verified April 2013 by Mayo Clinic

Sponsor:
Mayo Clinic

Information provided by (Responsible Party):
Su-Youne Chang, Mayo Clinic

ClinicalTrials.gov Identifier:
NCT01705301

First received: October 9, 2012
Last updated: April 26, 2013
Last verified: April 2013
[History of Changes](#)

[Full Text View](#)

[Tabular View](#)

[No Study Results Posted](#)

[Disclaimer](#)

[How to Read a Study Record](#)

► Purpose

In this study, the investigators will monitor extracellular neurotransmitter levels using a probe that is able to perform real time electrochemical detection during **deep brain stimulation** surgery. The overall question this study is designed to answer is: Are there neurotransmitters released during **deep brain stimulation**?

Condition	Intervention
Essential Tremor Parkinson's Disease Dystonia	Device: WINCS (Wireless Instantaneous Neurochemical Concentration Sensing System)

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Official Title: Neurotransmitter Measurements Using Wireless Instantaneous Neurotransmitter Concentration System (WINCS) During **Deep Brain Stimulation Neurosurgery**.

Trial Record
- Purpose
- Study Type
- Study Design
- Official Title

Resource links provided by NLM:

Genetics Home Reference related topics: [dopa-responsive dystonia](#) [early-onset primary dystonia](#) [essential tremor](#) [Parkinson disease](#) [Perry syndrome](#)

MedlinePlus related topics: [Dystonia](#) [Parkinson's Disease](#) [Tremor](#)

[U.S. FDA Resources](#)

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

- adenosine release in **brain** as measured by WINCS (Wireless Instantaneous Neurochemical Concentration Sensing System)recording device [Time Frame: 30 minutes] [Designated as safety issue: Yes]
Pre, during, post DBS (deep brain stimulation)

Secondary Outcome Measures:

- dopamine release in **brain** as measured by WINCS (Wireless Instantaneous Neurochemical Concentration Sensing System)recording device [Time Frame: 30 minutes] [Designated as safety issue: Yes]
Pre, during, post DBS (deep brain stimulation)

Estimated Enrollment: 45
Study Start Date: January 2010
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: WINCS WINCS (Wireless Instantaneous Neurochemical Concentration Sensing System), which is capable of wireless control and data transmission; and in addition is capable of detecting by fast scan cyclic voltametry (FSCV).	Device: WINCS (Wireless Instantaneous Neurochemical Concentration Sensing System) The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode

► Eligibility

Ages Eligible for Study: 18 Years to 90 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Trial Record (cont.)

- Resources
- Primary Outcomes
- Secondary Outcomes
- Estimated Enrollment
- Study Dates
- Eligibility

Exclusion Criteria:

- pregnant patients,
- prisoners,
- children (age less than 18), and
- any patients identified as unsuitable for these protocol by the Mayo DBS committee.

► **Contacts and Locations**

Please refer to this study by its ClinicalTrials.gov Identifier: NCT01705301

Locations

United States, Minnesota

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55901

Contact: Debra Gorman, RN 507-266-3044 gorman.deborah@mayo.edu

Principal Investigator: Kendall H Lee, MD, PhD

Principal Investigator: Su-youne Chang, PhD

Sponsors and Collaborators

Mayo Clinic

► **More Information**

No publications provided

Responsible Party: Su-Youne Chang, PI, Mayo Clinic

ClinicalTrials.gov Identifier: [NCT01705301](#) [History of Changes](#)

Other Study ID Numbers: 09-007441

Study First Received: October 9, 2012

Last Updated: April 26, 2013

Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:

Brain Diseases

Dystonia

Dystonic Disorders

Parkinson Disease

Tremor

Essential Tremor

Dyskinesias

Neurologic Manifestations

Nervous System Diseases

Signs and Symptoms

Movement Disorders

Central Nervous System Diseases

Parkinsonian Disorders

Basal Ganglia Diseases

Neurodegenerative Diseases

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Pharmacologic Actions

Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 06, 2013

Trial Record (cont.)

- **Contacts**
- **Locations**
- **Sponsors**
- **More Information**

▶ **Baseline Characteristics**

 [Show Baseline Characteristics](#)

▶ **Outcome Measures**

 [Show All Outcome Measures](#)

1. Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) Within 30 Days of the Procedure. [Time Frame: Up to 30 days after the procedure was performed]

 [Show Outcome Measure 1](#)

2. Secondary: Device Success [Time Frame: The entire duration of the index procedure]

 [Show Outcome Measure 2](#)

3. Secondary: Technical Success [Time Frame: The entire duration of the index procedure]

 [Show Outcome Measure 3](#)

4. Secondary: Procedural Success [Time Frame: The entire duration of the index procedure through hospital discharge]

 [Show Outcome Measure 4](#)

5. Secondary: Restenosis at 30 Days [Time Frame: Up to 30 days after the procedure was performed]

 [Show Outcome Measure 5](#)

6. Secondary: Target Lesion Revascularization at 30 Days [Time Frame: Up to 30 days after the procedure was performed]

 [Show Outcome Measure 6](#)

7. Secondary: Access Site Adverse Events [Time Frame: Index Procedure through Hospital Discharge]

 [Show Outcome Measure 7](#)

▶ **Serious Adverse Events**

 [Show Serious Adverse Events](#)

▶ **Other Adverse Events**

 [Show Other Adverse Events](#)

▶ **More Information**

 [Hide More Information](#)

Results (cont.)

- **Baseline Characteristics**
- **Outcome Measures**
- **Adverse Events**
- **More Information**

► Serious Adverse Events

Hide Serious Adverse Events

Time Frame	Index procedure through the 30 day follow-up visit.
Additional Description	No text entered.

Reporting Groups

	Description
MO.MA Roll-In Cases	All subjects who were enrolled prior to the pivotal phase of the trial at each US site. All subjects who fulfilled the eligibility criteria and were screened and enrolled to undergo carotid stenting with cerebral protection with the MO.MA proximal flow blockage cerebral protection device
MO.MA Pivotal Subjects	All subjects who fulfilled the eligibility criteria and were screened and enrolled to undergo carotid stenting with cerebral protection with the MO.MA proximal flow blockage cerebral protection device

Serious Adverse Events


	MO.MA Roll-In Cases	MO.MA Pivotal Subjects
Total, serious adverse events		
# participants affected / at risk	11/37 (29.73%)	37/225 (16.44%)
Blood and lymphatic system disorders		
Anaemia ^{*1}		
# participants affected / at risk	0/0 (0.00%)	4/225 (1.78%)
# events	0	4
Coagulopathy ^{*1}		
# participants affected / at risk	0/0 (0.00%)	1/225 (0.44%)
# events	0	1
Cardiac disorders		
Bradycardia ^{*1}		
# participants affected / at risk	1/37 (2.70%)	2/225 (0.89%)
# events	1	2
Cardiac failure congestive ^{*1}		
# participants affected / at risk	0/0 (0.00%)	1/225 (0.44%)
# events	0	1
Cardio-respiratory arrest ^{*1}		
# participants affected / at risk	0/0 (0.00%)	1/225 (0.44%)
# events	0	1
Coronary artery disease ^{*1}		
# participants affected / at risk	0/0 (0.00%)	1/225 (0.44%)
# events	0	1

Results (cont.)

- Adverse Events

eMerge Consortium

Informatics in Action



**Large-scale
genomic data
integrated
with clinical
workflow
through EHR
systems**

<http://www.genome.gov/27540473#a1-2>

SHRINE (Shared Health Research Information Network)

- Query across multiple institutions for research purposes
- Objectives
 - Increase data set size for analysis and detection of patterns
 - Share routine clinical data – not disease specific
 - Increase pool of individuals for clinical studies
 - Demonstrate cooperation across traditionally competing institutions

<http://catalyst.harvard.edu/services/shrine/>

SHRINE Query Interface

The screenshot displays the SHRINE Query Interface. On the left, a hierarchical tree of medical conditions is shown under the 'Navigate Terms' tab. A blue arrow points to 'Pervasive developmental disorders' under the 'Disorders usually diagnosed in infancy, childhood, or adolescence' category. The 'Find Terms' tab is also visible. On the right, the 'Query Tool' tab shows a query named 'Pervasive devel@12:38:55'. Below the query tool, the 'Query Status' panel displays the results of the finished query: 'Pervasive devel@12:38:55'. The results are summarized as follows:

Hospital	Patients	Status	Time
DFCI	26 ±3	FINISHED	3.0 secs
BIDMC	404 ±3	FINISHED	0.0 secs
CHB	9149 ±3	FINISHED	0.4 secs
Partners	5606 ±3	FINISHED	8.1 secs


Query: What is the distribution of individuals with pervasive developmental disorders across 5 collaborating hospitals?

Electronic Health Data for Predicting Risk

Informatics in Action

Bayesian model used to predict a patient's risk of receiving a future diagnosis of abuse, based on the patient's diagnostic history.

INJURY RISK: **HIGH**



Reis et al. BMJ 2009; Sep;339:b3677

Medicine at a Crossroads

- Petabytes of data are being collected
- Data need to be shared
- The data need to be stored, processed, filtered, visualized, integrated, and interpreted
- Social, legal, ethical, and economic issues need to be resolved

